Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿°»öü ¹Ì¼¼Çغο¡ ÀÇÇÑ ½Å¼¼Æ÷¾Ï ¼¼Æ÷ÁÖ Caki-1ÀÇ Ç¥Áö ¿°»öü ºÐ¼® Analysis of Marker Chromosomes in Renal Cell Carcinoma Cell Line Caki-1 by Chromosome Microdissection

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 3È£ p.205 ~ 212
¼Ò¼Ó »ó¼¼Á¤º¸
½ÅÀç¼·/Jae-Seop Shin ¹Ú¼ö¿¬/Àü¿ëÇõ/¹Ú¼±È­/Soo-Yeun Park/Yong-Hyuck Chun/Sun-Hwa Park

Abstract

°á·Ð
Á¾¾ç¿¡¼­ ÈçÈ÷ º¸ÀÌ´Â ¿°»öü ÀÌ»ó¿¡ ´ëÇÑ ¼¼Æ÷À¯ÀüÇÐÀû ºÐ¼®Àº ¸¹Àº Áúº´ÀÇ Áø´Ü°ú ¿¹ÈÄ
¸¦ ÆÇ´ÜÇϴµ¥ Áß¿äÇÑ ºÎºÐÀÌ µÇ¾ú°í, ºÐÀÚ ¼öÁØÀÇ ºÐ¼®Àº Á¾¾çÀÇ º´¸®±âÀü°ú °ü·ÃµÈ À¯Àü
ÀÚÀÇ ±Ô¸íÀ» ¿ëÀÌÇÏ°Ô ÇÏ°í ÀÖ´Ù. ±×·¯³ª °íÇü¾Ï¿¡¼­ º¸ÀÌ´Â ¸¹Àº Ç¥Áö ¿°»öüµéÀÇ º¯À̸¦
±Ô¸íÇÒ ¼ö ¾ø´Â °æ¿ì°¡ ´ëºÎºÐÀÌ´Ù.
º» ¿¬±¸´Â ƯÁ¤¿°»öü ÀÌ»ó°ú °ü·ÃÀÌ ¸¹´Ù°í º¸°íµÈ ½ÅÀå¾Ï¿¡¼­ À¯·¡ÇÑ ¼¼Æ÷ÁÖ Caki-1À»
ÇÙÇüºÐ¼®ÇÑ ÈÄ ±â¿øÀ» ¾Ë ¼ö ¾ø´Â ¿°»öü ºÎÀ§¸¦ ¹Ì¼¼ÇغÎÇÏ¿© probe poolÀ» ¸¸µç ÈÄ À̸¦
ÆäÀÎÆà probe·Î ÇÏ¿© FISH¹æ¹ýÀ¸·Î ±× Àý´ÜºÎÀ§¿Í º¯ÀÌµÈ ¿°»öüÀÇ ±â¿øÀ» ºÐ¼®ÇÏ°íÀÚ ÇÏ
¿´À¸¸ç CURC-II¿¡ Àû¿ëÇÏ¿© Ç¥Áö¿°»öü¸¦ ºñ±³ÇÏ¿´´Ù.
Caki-1ÀÇ Ç¥Áö¿°»öüÀÎ 9q+¿Í À¯·¡¸¦ ¾Ë ¼ö ¾ø´Â Ç¥Áö¿°»öü¸¦ ¹Ì¼¼ÇغÎÇÑ ÈÄ
Topolsornejase¿Í T7 DNA polymerase¸¦ »ç¿ëÇÑ PCR ¹æ¹ýÀ¸·Î ¿°»öü DNA ÁõÆøÀ» ¾ò¾ú
´Ù. ÁõÆøµÈ DNA »ê¹°À» biotinÀ¸·Î Ç¥ÁöÇÏ¿© Çü±¤ in situ hybridization¹ýÀ» ÀÌ¿ëÇÏ¿© ÆäÀÎ
ÆÃÇÑ °á°ú ¹Ì¼¼ÇØºÎµÈ ¿°»öüºÎÀ§¿¡ °áÇյǾî ÀûÀýÇÑ ÆäÀÎÆà probe Á¦ÀÛÀ» È®ÀÎÇÏ¿´°í, Á¤
»ó ¿°»öü¿¡ °áÇÕ½ÃŲ °á°ú ±× À¯·¡ÇÑ ¿°»öüºÎÀ§¸¦ ±Ô¸íÇÒ ¼ö ÀÖ¾ú´Ù. 9q+´Â
t(9;17)(q34;q21)¿´°í, À¯·¡¸¦ ¾Ë ¼ö ¾ø¾ú´ø Ç¥Áö¿°»öü´Â t(15;20)·Î ¹àÇôÁ³´Ù. À̵é probe¸¦
CURC-II¿¡ Àû¿ëÇÏ¿© ºñ±³ºÐ¼®ÇÑ °á°ú t(9,17), der(1;17)(q10;q10), t(15;20), t(?;15),
der(1,20), t(14;19) Ç¥Áö¿°»öü°¡ µ¿ÀÏÇÏ°Ô ¹ß°ßµÇ¾î ±× ÀüÀ§µÈ ¿°»öüºÎÀ§°¡ ½Å¼¼Æ÷¾Ï°ú ¹Ð
Á¢ÇÑ °ü·Ã¼ºÀÌ ÀÖÀ½À» ÃßÃøÇÏ°Ô ÇÏ¿´´Ù.
±×·¯¹Ç·Î ÀÌ»óÀÇ ¹æ¹ýÀº ºÐ¼®ÀÌ °ï¶õÇÑ Ç¥Áö¿°»öü¿¡ Àû¿ëµÇ¾î ±× ±â¿øÀ» ºÐ¼®Çϴµ¥ À¯¿ë
ÇÏ°Ô ¾²ÀÏ ¼ö ÀÖÀ¸¸ç, Á¦ÀÛµÈ ÆäÀÎÆà probe´Â ½Å¼¼Æ÷¾Ï¿¡ Àû¿ëµÇ¾î À¯»çÇÑ Ç¥Áö¿°»öü¸¦ ±¸
ºÐÇϴµ¥ ÀÌ¿ëµÉ »Ó ¾Æ´Ï¶ó probe poolsÀº ¾ÆÁ÷ ¾Ë·ÁÁöÁö ¾ÊÀº ¾Ï°ú °ü·ÃµÈ »õ·Î¿î À¯ÀüÀÚ
¸¦ ±Ô¸íÇÏ´Â µ¥¿¡µµ ÀÌ¿ëµÉ ¼ö ÀÖÀ» °ÍÀÌ´Ù.
#ÃÊ·Ï#
Purpose : The analysis of recurring chromosome aberrations has become an integral
part of the diagnostic and prognostic workup of many human cancers, and their
molecular analyses have facilitated the identification of genes related to the pathogenesis
of cancer But the technical limitation of conventional cytogenetic method makes unable
us to characterize all recognizable chromosome rearrangements. The generation of
chromosome region specific painting probe by PCR amplification of microdissected
chromosomal DNA has proven extremely useful in identification of chromosomal
derivation for marker chromosomes which are indeterminable by routine chromosome
banding analysis. In this study we have constructed and analyzed the band-specific
painting probe for unidentified marker chromosomes of renal cell carcinoma cell line,
Caki-1 to determine the derivative chromosomes and the painting probes applied to
CURC-II to compare the marker chromosomes.
Materials and Methods: Microdissection was performed on 9q+ and unidentified one of
Caki-1, and chromosomal BNAs were amplified by PCR using topoisomerase I and T7
DNA polymerase. Fluorescent in situ hybridization was conducted with biotin labeled
PCR products to normal, Caki-1 and CURC- II metaphase chromosomes.
Results: With this method, it was possible to construct the band-specific painting
probes for markers and the probes hybridized specifically to the dissected regions and
derivative chromosomes. The 9q+ and unidentified one were identified as t(9;17)(q34;q21)
and t(15;20) respectively. The marker chromosomes - t(9;I 7), der(1 ;17)(ql0;q10),
t(15;20), t(?;15), der(1 ;20), t(14;89) were examined same in Caki-1 and CURC-II.
Conclusions: Thus this methodological advance significantly extends the limits of
conventional cytogenetic analysis by enabling the analysis of unknown chromosome
regions, and these painting probes can be applied to detect the similar marker
chromosomes in renal cell carcinoma, and the probe pools for markeys may be used to
identify the cancer-relevant genes.

Å°¿öµå

Caki-I; CURC-II; Marker chromosome; Chromosome microdissection; Fluorescent in situ hybridization;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS